86 related articles for article (PubMed ID: 2243541)
1. Buprenorphine-induced pupillary effects in human volunteers.
Pickworth WB; Lee H; Fudala PJ
Life Sci; 1990; 47(14):1269-77. PubMed ID: 2243541
[TBL] [Abstract][Full Text] [Related]
2. Intravenous buprenorphine reduces pupil size and the light reflex in humans.
Pickworth WB; Bunker E; Welch P; Cone E
Life Sci; 1991; 49(2):129-38. PubMed ID: 2062170
[TBL] [Abstract][Full Text] [Related]
3. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal.
Fudala PJ; Jaffe JH; Dax EM; Johnson RE
Clin Pharmacol Ther; 1990 Apr; 47(4):525-34. PubMed ID: 2328561
[TBL] [Abstract][Full Text] [Related]
4. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine.
Kuhlman JJ; Levine B; Johnson RE; Fudala PJ; Cone EJ
Addiction; 1998 Apr; 93(4):549-59. PubMed ID: 9684393
[TBL] [Abstract][Full Text] [Related]
5. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction.
Johnson RE; Cone EJ; Henningfield JE; Fudala PJ
Clin Pharmacol Ther; 1989 Sep; 46(3):335-43. PubMed ID: 2776393
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin.
Oreskovich MR; Saxon AJ; Ellis ML; Malte CA; Reoux JP; Knox PC
Drug Alcohol Depend; 2005 Jan; 77(1):71-9. PubMed ID: 15607843
[TBL] [Abstract][Full Text] [Related]
7. Intravenous buprenorphine self-administration by detoxified heroin abusers.
Comer SD; Collins ED; Fischman MW
J Pharmacol Exp Ther; 2002 Apr; 301(1):266-76. PubMed ID: 11907183
[TBL] [Abstract][Full Text] [Related]
8. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans.
Greenwald MK; Schuh KJ; Hopper JA; Schuster CR; Johanson CE
Psychopharmacology (Berl); 2002 Apr; 160(4):344-52. PubMed ID: 11919661
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine suppresses heroin use by heroin addicts.
Mello NK; Mendelson JH
Science; 1980 Feb; 207(4431):657-9. PubMed ID: 7352279
[TBL] [Abstract][Full Text] [Related]
10. Subjective and physiologic effects of intravenous buprenorphine in humans.
Pickworth WB; Johnson RE; Holicky BA; Cone EJ
Clin Pharmacol Ther; 1993 May; 53(5):570-6. PubMed ID: 8491067
[TBL] [Abstract][Full Text] [Related]
11. Alternate-day dosing during buprenorphine treatment of opioid dependence.
Amass L; Bickel WK; Higgins ST; Badger GJ
Life Sci; 1994; 54(17):1215-28. PubMed ID: 8164503
[TBL] [Abstract][Full Text] [Related]
12. Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence.
Kakko J; von Wachenfeldt J; Svanborg KD; Lidström J; Barr CS; Heilig M
Biol Psychiatry; 2008 Jan; 63(2):172-7. PubMed ID: 17850768
[TBL] [Abstract][Full Text] [Related]
13. Effects of indatraline and buprenorphine on self-administration of speedball combinations of cocaine and heroin by rhesus monkeys.
Mello NK; Negus SS
Neuropsychopharmacology; 2001 Jul; 25(1):104-17. PubMed ID: 11377924
[TBL] [Abstract][Full Text] [Related]
14. Alfentanil blocks reflex pupillary dilation in response to noxious stimulation but does not diminish the light reflex.
Larson MD; Kurz A; Sessler DI; Dechert M; Bjorksten AR; Tayefeh F
Anesthesiology; 1997 Oct; 87(4):849-55. PubMed ID: 9357887
[TBL] [Abstract][Full Text] [Related]
15. Sublingual versus subcutaneous buprenorphine in opiate abusers.
Jasinski DR; Fudala PJ; Johnson RE
Clin Pharmacol Ther; 1989 May; 45(5):513-9. PubMed ID: 2721107
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
Ciraulo DA; Hitzemann RJ; Somoza E; Knapp CM; Rotrosen J; Sarid-Segal O; Ciraulo AM; Greenblatt DJ; Chiang CN
J Clin Pharmacol; 2006 Feb; 46(2):179-92. PubMed ID: 16432270
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine effects on plasma luteinizing hormone and prolactin in male heroin addicts.
Mendelson JH; Ellingboe J; Mello NK; Kuehnle J
J Pharmacol Exp Ther; 1982 Feb; 220(2):252-5. PubMed ID: 7057390
[TBL] [Abstract][Full Text] [Related]
19. [Feature extraction and pupil size detection of pupillary light reflex in opiate addicts].
Zeng T; Shi YT; Peng QB; Chen NH; Ma YY
Dongwuxue Yanjiu; 2010 Aug; 31(4):415-20. PubMed ID: 20740704
[TBL] [Abstract][Full Text] [Related]
20. Assessment of pupil size during acute heroin withdrawal in Viet Nam.
Robinson MG; Howe RC; Varni JG; Ream NW; Hegge FW
Neurology; 1974 Aug; 24(8):729-32. PubMed ID: 4858730
[No Abstract] [Full Text] [Related]
[Next] [New Search]
